Aligos Therapeutics, Inc.
ALGS
$4.08
$0.092.26%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -50.43% | 19.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -50.43% | 19.60% | |||
| Cost of Revenue | -4.43% | -20.50% | |||
| Gross Profit | 0.66% | 22.62% | |||
| SG&A Expenses | 11.57% | -27.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.97% | -22.11% | |||
| Operating Income | -2.15% | 23.79% | |||
| Income Before Tax | -328.44% | -465.10% | |||
| Income Tax Expenses | -70.33% | -51.85% | |||
| Earnings from Continuing Operations | -326.55% | -480.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -326.55% | -480.54% | |||
| EBIT | -2.15% | 23.79% | |||
| EBITDA | -2.21% | 23.99% | |||
| EPS Basic | -325.89% | -479.64% | |||
| Normalized Basic EPS | -327.77% | -464.30% | |||
| EPS Diluted | -325.89% | -509.40% | |||
| Normalized Diluted EPS | -327.77% | -464.71% | |||
| Average Basic Shares Outstanding | 0.16% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
